These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 25540891)

  • 1. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
    Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
    Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
    Mwesigwa B; Houser KV; Hofstetter AR; Ortega-Villa AM; Naluyima P; Kiweewa F; Nakabuye I; Yamshchikov GV; Andrews C; O'Callahan M; Strom L; Schech S; Anne Eller L; Sondergaard EL; Scott PT; Amare MF; Modjarrad K; Wamala A; Tindikahwa A; Musingye E; Nanyondo J; Gaudinski MR; Gordon IJ; Holman LA; Saunders JG; Costner PJM; Mendoza FH; Happe M; Morgan P; Plummer SH; Hickman SP; Vazquez S; Murray T; Cordon J; Dulan CNM; Hunegnaw R; Basappa M; Padilla M; Gajjala SR; Swanson PA; Lin BC; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Kibuuka H; Ake JA; Ledgerwood JE;
    Lancet Infect Dis; 2023 Dec; 23(12):1408-1417. PubMed ID: 37544326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W
    Lancet; 2015 Jun; 385(9984):2272-9. PubMed ID: 25817373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
    Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
    Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
    De Santis O; Audran R; Pothin E; Warpelin-Decrausaz L; Vallotton L; Wuerzner G; Cochet C; Estoppey D; Steiner-Monard V; Lonchampt S; Thierry AC; Mayor C; Bailer RT; Mbaya OT; Zhou Y; Ploquin A; Sullivan NJ; Graham BS; Roman F; De Ryck I; Ballou WR; Kieny MP; Moorthy V; Spertini F; Genton B
    Lancet Infect Dis; 2016 Mar; 16(3):311-20. PubMed ID: 26725450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
    Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
    Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimpanzee Adenovirus Vector Ebola Vaccine.
    Ledgerwood JE; DeZure AD; Stanley DA; Coates EE; Novik L; Enama ME; Berkowitz NM; Hu Z; Joshi G; Ploquin A; Sitar S; Gordon IJ; Plummer SA; Holman LA; Hendel CS; Yamshchikov G; Roman F; Nicosia A; Colloca S; Cortese R; Bailer RT; Schwartz RM; Roederer M; Mascola JR; Koup RA; Sullivan NJ; Graham BS;
    N Engl J Med; 2017 Mar; 376(10):928-938. PubMed ID: 25426834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.
    Sarwar UN; Costner P; Enama ME; Berkowitz N; Hu Z; Hendel CS; Sitar S; Plummer S; Mulangu S; Bailer RT; Koup RA; Mascola JR; Nabel GJ; Sullivan NJ; Graham BS; Ledgerwood JE;
    J Infect Dis; 2015 Feb; 211(4):549-57. PubMed ID: 25225676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
    Martin JE; Sullivan NJ; Enama ME; Gordon IJ; Roederer M; Koup RA; Bailer RT; Chakrabarti BK; Bailey MA; Gomez PL; Andrews CA; Moodie Z; Gu L; Stein JA; Nabel GJ; Graham BS
    Clin Vaccine Immunol; 2006 Nov; 13(11):1267-77. PubMed ID: 16988008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.